BIOVENTUS INC. Income Charts

8 quarters of history · ending 2025-12-31 · SEC EDGAR

Source:10-K · 10-Q

Revenue, Gross Profit, Operating Income & Net Income

Margin (%)

Operating Expenses

Income Breakdown

Revenue↑+2.8% +$4M
$158M
Cost of Revenue↓-3.7% -$2M
$49M
Gross Profit↑+6.0% +$6M
$109M
R&D↓-8.1% -$264K
$3M
SG&A↓-4.7% -$4M
$83M
D&A↓-5.7% -$711K
$12M
Operating Income
$19M
EBITDA↑+151.4% +$19M
$31M
Interest Expense↑+35.2% +$3M
$-6M
Other Income/Expense
$-5M
Pretax Income
$14M
Tax Provision↑+12.7% +$75K
$664K
Net Income
$15M
Gross Margin↑+2.1pts
68.9%
Operating Margin
12.3%
Net Margin
9.3%
Effective Tax Rate↑+25.4pts
14.2%
Deferred Tax Assets↓-100.0% -$512K
$0
Deferred Tax Liabilities
$135K
Tax Credit Carryforwards↑+126.0% +$1M
$2M
ETR (Continuing Operations)↓-16.2pts
-6.1%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-1.2pts
1.0%
ETR Foreign Differential (pp)
-0.6%
Operating Lease CostNEW↓-18.3% -$144K
$642K
Revenue YoY Variation↓-10.7pts
2.8%
Income YoY Variation↑+157.7pts
208.5%
Revenue QoQ Variation↑+3.3pts
13.9%
Income QoQ Variation
73.2%
No segment data available for this ticker. Source: quarterchart.com.

BIOVENTUS INC. — SEC R-Report Segment ScorecardNEW

One card per operating segment. KPIs read the latest disclosed value (issuer-precomputed margin and YoY %, not recomputed client-side). Sparkline shows the 3-period revenue trend. Source: SEC EDGAR R-reports.

US

Revenue (latest)$502M
Margin
YoY-0.9%

3-period revenue trend

International

Revenue (latest)$66M
Margin
YoY-0.7%

3-period revenue trend

BIOVENTUS INC. — Revenue & Assets by GeographyNEW

Per-country / per-region revenue + long-lived non-current assets sourced from the issuer's 10-K dimensional XBRL on srt:StatementGeographicalAxis. Higher-level aggregates (Non Us) hidden to avoid double-counting.

United States

$248.2Mrev

Non Us

$30.8Mrev

BIOVENTUS INC. — Customer & Supplier ConcentrationNEW

Major-customer and supplier-side disclosures sourced from srt:MajorCustomersAxis dimensional XBRL. Coverage is ~44% of the S&P 500 (sparser than other panels) but high-value when present — a 20%+ single-counterparty exposure is a headline business risk required to be disclosed in 10-K MD&A under Reg S-K Item 101.Largest single-counterparty concentration this period: 28%.

Customer-Side Concentration

End-customer dependence — single-customer % of revenue. NVDA Customer 1 = 25%, AVGO Major Customer 1 = 32%.

As of 2025-12-31 · 1 row

CounterpartyKindConcentrationRevenue / Spend
Customer 1customer
28.1%
$64.5M